First topical JAK inhibitor approved in the USA

Provides early and sustained improvements in disease severity, pruritus and sleep disturbance measures when applied twice daily over the short term

Controls disease severity measures when applied as needed to active lesions over the longer term

Safety profile similar to that of vehicle cream; no safety findings suggestive of systemic JAK inhibition